Peter Heerma Sells 1,584 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Peter Heerma sold 1,584 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total transaction of $30,000.96. Following the transaction, the insider now owns 106,374 shares in the company, valued at approximately $2,014,723.56. The trade was a 1.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Travere Therapeutics Price Performance

TVTX stock traded up $1.35 during trading on Thursday, hitting $20.81. 2,031,403 shares of the stock traded hands, compared to its average volume of 1,331,242. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -4.57 and a beta of 0.70. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $20.89. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The company has a 50 day simple moving average of $18.28 and a 200 day simple moving average of $14.79.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. The company had revenue of $62.90 million during the quarter, compared to analysts’ expectations of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. Travere Therapeutics’s quarterly revenue was up 69.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.17) earnings per share. Equities analysts expect that Travere Therapeutics, Inc. will post -3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on TVTX. Guggenheim upped their price target on Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Piper Sandler raised their target price on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. Bank of America boosted their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Barclays raised their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Finally, Wedbush upped their target price on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors have recently bought and sold shares of the business. Baader Bank Aktiengesellschaft bought a new stake in shares of Travere Therapeutics during the fourth quarter worth $192,000. R Squared Ltd bought a new position in shares of Travere Therapeutics in the fourth quarter valued at about $53,000. Diversified Trust Co lifted its position in Travere Therapeutics by 27.5% during the 4th quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock worth $256,000 after buying an additional 3,169 shares in the last quarter. Virtu Financial LLC bought a new stake in Travere Therapeutics during the 3rd quarter worth about $301,000. Finally, Geode Capital Management LLC grew its holdings in Travere Therapeutics by 3.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock worth $24,222,000 after acquiring an additional 64,744 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.